Seres Therapeutics (MCRB) Reports Q2 Loss of $0.69/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
August 3, 2017 7:05 AM EDT- Initiated SER-109 Phase 3 study in patients with multiply recurrent C. difficile infection -
- SER-287 Phase 1b study in mild-to-moderate ulcerative colitis patients, failing first line therapy, fully enrolled;Â Top-line data read-out expected in the second half of 2017 -
- Conference call at 8 a.m. ET today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc.... More
